Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, mRNA), Type (Multivalent, Monovalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, Rotavirus, RSV, HPV, Polio), ROA (IM, SC, Oral), Competition - Global Forecast to 2031
Description
The vaccines market (excluding COVID-19) is expected to reach USD 71.14 billion in 2031, up from USD 55.68 billion in 2026, growing at a CAGR of 5.0% during the forecast period. Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth in vaccines.
By disease indication, the pneumococcal segment accounted for the largest share of the vaccines market in 2025.
Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. In 2025, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits.
By type, the multivalent vaccines segment accounted for the largest share of the vaccines market in 2025.
The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2025, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance stems from multivalent vaccines' ability to protect against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.
The Asia Pacific region is expected to grow at the highest CAGR in the vaccines market from 2026 to 2031.
The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage
This research report categorizes the vaccines market by technology (conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines), type (monovalent vaccines and multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, COVID-19, and other disease indications), route of administration (intramuscular & subcutaneous administration, oral administration, and other routes of administration), end user (pediatric vaccines and adult vaccines), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. This report includes a competitive analysis of top players and upcoming startups within the vaccines market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, and government support & funding for vaccine development), restraints (high cost of vaccine development), opportunities (rising focus on therapeutic vaccines, extensive R&D for vaccines, and increased investments in clinical trials), and challenges (stringent regulatory processes and product recalls)
The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments and funding, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines market.
By disease indication, the pneumococcal segment accounted for the largest share of the vaccines market in 2025.
Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. In 2025, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits.
By type, the multivalent vaccines segment accounted for the largest share of the vaccines market in 2025.
The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2025, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance stems from multivalent vaccines' ability to protect against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.
The Asia Pacific region is expected to grow at the highest CAGR in the vaccines market from 2026 to 2031.
The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (80%) and Demand Side (20%)
- By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
Research Coverage
This research report categorizes the vaccines market by technology (conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines), type (monovalent vaccines and multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, COVID-19, and other disease indications), route of administration (intramuscular & subcutaneous administration, oral administration, and other routes of administration), end user (pediatric vaccines and adult vaccines), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. This report includes a competitive analysis of top players and upcoming startups within the vaccines market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.
Key Benefits of Buying the Report
This report offers a comprehensive overview of the vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, and government support & funding for vaccine development), restraints (high cost of vaccine development), opportunities (rising focus on therapeutic vaccines, extensive R&D for vaccines, and increased investments in clinical trials), and challenges (stringent regulatory processes and product recalls)
- Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the vaccines market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the vaccines market across varied regions.
- Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the vaccines market
The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments and funding, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines market.
Table of Contents
440 Pages
- 1 Introduction
- 1.1 Study Objectives
- 1.2 Market Definition
- 1.3 Study Scope
- 1.3.1 Market Segmentation & Regions Covered
- 1.3.2 Inclusions & Exclusions
- 1.3.3 Years Considered
- 1.3.4 Currency Considered
- 1.4 Stakeholders
- 1.5 Summary Of Changes
- 2 Executive Summary
- 2.1 Market Highlights And Key Insights
- 2.2 Key Market Participants: Mapping Of Strategic Developments
- 2.3 Disruptive Trends In Vaccines Market
- 2.4 High-growth Segments
- 2.5 Regional Snapshot: Market Size, Growth Rate, And Forecast
- 3 Premium Insights
- 3.1 Vaccines Market Overview
- 3.2 North America: Vaccines Market (Excluding Covid-19 Vaccines), By Type And Country, 2025
- 3.3 Vaccines Market (Excluding Covid-19 Vaccines): Geographic Growth Opportunities
- 3.4 Vaccines Market (Excluding Covid-19 Vaccines) Share, By Route Of Administration, 2026 Vs 2031 (%)
- 4 Market Overview
- 4.1 Introduction
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.1.1 Focus On Vaccine Development And Launches
- 4.2.1.2 Rising Prevalence Of Infectious Diseases
- 4.2.1.3 Increasing Immunization Programs
- 4.2.1.4 Advancements In Vaccine Technology
- 4.2.1.5 Government Support And Funding For Vaccine Development
- 4.2.2 Restraints
- 4.2.2.1 High Cost Of Vaccine Development
- 4.2.3 Opportunities
- 4.2.3.1 Rising Focus On Therapeutic Vaccines
- 4.2.3.2 Extensive R&D For Vaccines And Increased Investments In Clinical Trials
- 4.2.4 Challenges
- 4.2.4.1 Stringent Regulatory Processes
- 4.2.4.2 Product Recalls
- 4.3 Unmet Needs & White Spaces
- 4.4 Interconnected Markets & Cross-sector Opportunities
- 4.5 Strategic Moves By Tier-1/2/3 Players
- 5 Industry Trends
- 5.1 Porter’s Five Forces Analysis
- 5.1.1 Bargaining Power Of Suppliers
- 5.1.2 Bargaining Power Of Buyers
- 5.1.3 Threat Of New Entrants
- 5.1.4 Threat Of Substitutes
- 5.1.5 Intensity Of Competitive Rivalry
- 5.2 Macroeconomic Outlook
- 5.2.1 Introduction
- 5.2.2 Gdp Trends & Forecast
- 5.2.3 Trends In Global Vaccines Industry
- 5.3 Value Chain Analysis
- 5.4 Pipeline Analysis
- 5.4.1 Vaccines Market: Clinical Trials, By Phase
- 5.4.2 Vaccines Market: Clinical Trials, By Disease Indication
- 5.4.3 Vaccines Market: Phase 2/3 Clinical Trials, By Company
- 5.5 Ecosystem Analysis
- 5.6 Pricing Analysis
- 5.6.1 Average Selling Price Trend, By Key Player, 2024–2026
- 5.6.2 Average Selling Price Trend, By Disease Indication, 2024–2026
- 5.6.3 Average Selling Price Trend, By Region, 2022–2024
- 5.7 Trade Analysis
- 5.7.1 Import Scenario (Hs Code 300220)
- 5.7.2 Export Scenario (Hs Code 300220)
- 5.8 Key Conferences And Events, 2026–2027
- 5.9 Trends/Disruptions Impacting Customers’ Business
- 5.10 Investment And Funding Scenario
- 5.10.1 Vc/Private Equity Investment Trends & Startup Landscape
- 5.11 Impact Of 2025 Us Tariffs—vaccines Market
- 5.11.1 Introduction
- 5.11.2 Key Tariff Rates
- 5.11.3 Price Impact Analysis
- 5.11.4 Impact On Countries/Regions
- 5.11.4.1 Us
- 5.11.4.2 Europe
- 5.11.4.3 Asia Pacific
- 5.11.5 Impact On End-use Industries
- 5.11.5.1 Public Health & Government Bodies
- 5.11.5.2 Healthcare Providers & Institutions
- 5.12 Vaccine Procurement Data
- 5.12.1 Number Of Vaccines Delivered By Unicef, 2024–2026
- 5.12.2 Who: Vaccine Purchase Database, 2022–2024
- 5.13 Vaccine Manufacturing Process
- 5.13.1 Overview
- 5.13.1.1 R&D And Process Development
- 5.13.1.2 Upstream Production (Antigen Generation)
- 5.13.1.3 Downstream Processing
- 5.13.1.4 Formulation & Fill-finish
- 5.13.1.5 Quality Control & Regulatory Release
- 5.13.1.6 Packaging, Cold Chain, And Distribution
- 5.13.2 Manufacturing Models & Capacity Dynamics
- 6 Technological Advancements, Ai-driven Impact, Patents, And Innovations
- 6.1 Technology Analysis
- 6.1.1 Key Emerging Technologies
- 6.1.1.1 Recombinant Technology
- 6.1.1.2 Conjugation Technology
- 6.1.1.3 Viral Vector Technology
- 6.1.2 Complementary Technologies
- 6.1.2.1 Encapsulation & Delivery Technology
- 6.1.2.2 Automation & Control
- 6.1.2.3 Ai & Machine Learning For Vaccine Design
- 6.1.3 Adjacent Technologies
- 6.1.3.1 Single-use Technology
- 6.1.3.2 Cell Line Development
- 6.2 Technology/Product Roadmap
- 6.3 Patent Analysis
- 6.3.1 Top Applicants/Owners (Companies) For Vaccine Patents
- 6.4 Future Applications
- 6.5 Impact Of Ai/Gen Ai—vaccines Market
- 6.5.1 Best Practices In Vaccines Workflow
- 6.5.2 Case Studies Of Ai Implementation In Vaccines Market
- 6.5.3 Interconnected Adjacent Ecosystems & Impact On Market Players
- 6.5.4 Clients’ Readiness To Adopt Generative Ai In Vaccines Market
- 7 Regulatory Landscape And Sustainability Initiatives
- 7.1 Regional Regulations And Compliance
- 7.1.1 Regulatory Bodies, Government Agencies, And Other Organizations
- 7.1.2 Regulatory Framework
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 Asia Pacific
- 7.1.2.4 Latin America
- 7.1.2.5 Middle East & Africa
- 7.1.3 Regulatory Challenges In Vaccines Market
- 7.1.4 Industry Standards
- 7.2 Sustainability Initiatives
- 7.3 Impact Of Regulatory Policies On Sustainability
- 7.4 Certifications, Labeling, And Eco-standards
- 8 Customer Landscape & Buyer Behavior
- 8.1 Decision-making Process
- 8.2 Buyer Stakeholders & Buying Evaluation Criteria
- 8.2.1 Key Stakeholders In Buying Process
- 8.2.2 Key Buying Criteria, By End User
- 8.3 Adoption Barriers & Internal Challenges
- 8.4 Unmet Needs From Various End-use Industries
- 8.5 Market Profitability
- 9 Vaccines Market, By Disease Indication
- 9.1 Introduction
- 9.2 Pneumococcal Disease
- 9.2.1 Expanding Adult Immunization Programs And Higher-valency Vaccines To Drive Market
- 9.3 Influenza
- 9.3.1 Seasonal Immunization Programs And Expanding Adult Vaccination To Drive Market
- 9.4 Hpv
- 9.4.1 Expanding National Hpv Immunization Programs And Rising Adoption Of Gender-neutral Vaccination To Drive The Fastest-growing Segment
- 9.5 Herpes Zoster
- 9.5.1 Rising Aging Population To Drive Demand For Herpes Zoster Vaccines
- 9.6 Combination Vaccines
- 9.6.1 Expanding National Immunization Programs And Growing Preference For Multi-antigen Vaccines To Drive Market
- 9.7 Meningococcal Disease
- 9.7.1 Expanding Immunization Recommendations And Broader Serogroup Coverage To Support Market Growth
- 9.8 Rotavirus
- 9.8.1 Rising Infant Immunization Programs To Drive Rotavirus Market Growth
- 9.9 Rsv
- 9.9.1 Initial Vaccine Uptake And Expanding Immunization Recommendations Support Market Penetration
- 9.10 Dtp
- 9.10.1 Continued Routine Childhood Immunization And Booster Vaccination Programs To Support Market
- 9.11 Hepatitis
- 9.11.1 Expanding Hepatitis B Immunization And Global Elimination Initiatives To Support Market Growth
- 9.12 Varicella
- 9.12.1 Expanding Childhood Immunization Programs And Increasing Adoption Of Varicella Vaccines To Support Market Growth
- 9.13 Mmr
- 9.13.1 Rising Measles Outbreaks And Immunization Recovery Efforts To Support Market Growth
- 9.14 Polio
- 9.14.1 Global Polio Eradication Initiatives And Continued Vaccination Campaigns To Sustain Market Demand
- 9.15 Covid-19
- 9.15.1 Shift From Pandemic-driven Demand To Enduring High-risk Population Vaccination, Resulting In Market Normalization
- 9.16 Other Disease Indications
- 10 Vaccines Market, By Technology
- 10.1 Introduction
- 10.2 Vaccines Market (Excluding Covid-19 Vaccines), By Technology
- 10.2.1 Recombinant Vaccines
- 10.2.1.1 Broader Adult Immunization And Continued Recombinant Vaccine Launches To Drive Market
- 10.2.2 Conjugate Vaccines
- 10.2.2.1 Higher-valency Pneumococcal Vaccines And Large Public Immunization Programs To Drive Market
- 10.2.3 Inactivated & Subunit Vaccines
- 10.2.3.1 Recurring Influenza Demand And Wider Access To Established Non-live Vaccines To Support Market
- 10.2.4 Live Attenuated Vaccines
- 10.2.4.1 Durable Immune Protection And Convenient Oral Or Nasal Administration To Support Market
- 10.2.5 Toxoid Vaccines
- 10.2.5.1 Routine Pediatric Boosters And Maternal Immunization Programs To Sustain Market
- 10.2.6 Other Vaccines
- 10.3 Covid-19 Vaccines Market, By Technology
- 10.3.1 Mrna Vaccines
- 10.3.1.1 Rapid Variant Adaptation And Continued Vaccination Of High-risk Populations To Drive Market
- 10.3.2 Viral Vector Vaccines
- 10.3.2.1 Withdrawal Of First-generation Products And Shift Toward Updated Vaccine Platforms To Accelerate Market Decline
- 10.3.3 Other Covid-19 Vaccines
- 11 Vaccines Market (Excluding Covid-19 Vaccines), By Type
- 11.1 Introduction
- 11.2 Multivalent Vaccines
- 11.2.1 Broader Serotype Coverage And Increasing Adoption Of Combination Immunization Schedules To Drive Market
- 11.3 Monovalent Vaccines
- 11.3.1 Established Single-disease Programs And Expanding Adult Immunization Indications To Support Market
- 12 Vaccines Market (Excluding Covid-19 Vaccines), By Route Of Administration
- 12.1 Introduction
- 12.2 Intramuscular & Subcutaneous Administration
- 12.2.1 Ease Of Absorption And Better Immune Response To Drive Adoption
- 12.3 Oral Administration
- 12.3.1 Needle-free Delivery And High-volume Disease-control Campaigns To Support Market
- 12.4 Other Routes Of Administration
- 13 Vaccines Market (Excluding Covid-19 Vaccines), By End User
- 13.1 Introduction
- 13.2 Adult Vaccines
- 13.2.1 Aging Populations, Broader Adult Indications, And Growing Life-course Immunization To Drive Market
- 13.3 Pediatric Vaccines
- 13.3.1 Expanding Childhood Immunization Schedules And New Vaccine Introductions To Drive Market Growth
- 14 Vaccines Market (Excluding Covid-19 Vaccines), By Region
- 14.1 Introduction
- 14.2 North America
- 14.2.1 Us
- 14.2.1.1 Us To Dominate North American Market During Forecast Period
- 14.2.2 Canada
- 14.2.2.1 Expansion Of Life-course Immunization To Support Market Growth
- 14.3 Europe
- 14.3.1 Germany
- 14.3.1.1 Adult Immunization And Updated National Recommendations To Drive Market Growth
- 14.3.2 Uk
- 14.3.2.1 Expansion Of Adult And Maternal Immunization Programs To Support Market Growth
- 14.3.3 France
- 14.3.3.1 Favorable Government Initiatives For Mass Immunization To Drive Market
- 14.3.4 Italy
- 14.3.4.1 Higher Investments By Companies For Increased Production Capacities To Drive Market
- 14.3.5 Spain
- 14.3.5.1 Rising Investments In Vaccine Development By Private Organizations To Drive Market
- 14.3.6 Rest Of Europe
- 14.4 Asia Pacific
- 14.4.1 China
- 14.4.1.1 China To Hold Largest Share Of Apac Vaccines Market
- 14.4.2 Japan
- 14.4.2.1 Aging Population And Gradual Expansion Of Routine Vaccination To Drive Demand
- 14.4.3 India
- 14.4.3.1 Large Immunization Requirements And Manufacturing Leadership To Support Strong Growth
- 14.4.4 South Korea
- 14.4.4.1 Strong Government Strategies For Improved Vaccine Hubs To Drive Market
- 14.4.5 Rest Of Asia Pacific
- 14.5 Latin America
- 14.5.1 Brazil
- 14.5.1.1 Strong Public Procurement And Domestic Manufacturing To Drive Market
- 14.5.2 Mexico
- 14.5.2.1 Trained Workforce And Ethnically Varied Population Base For Clinical Trials To Propel Market Growth
- 14.5.3 Rest Of Latin America
- 14.6 Middle East
- 14.6.1 Government-led Localization And Expanding Adult And Travel Immunization To Support Market Growth
- 14.7 Africa
- 14.7.1 High Unmet Immunization Needs And Local Manufacturing Initiatives To Drive Market Expansion
- 15 Competitive Landscape
- 15.1 Overview
- 15.2 Key Player Strategies/Right To Win
- 15.2.1 Overview Of Strategies Adopted By Players In Vaccines Market
- 15.3 Revenue Analysis, 2021–2025
- 15.4 Market Share Analysis, 2025
- 15.5 Company Evaluation Matrix: Key Players, 2025
- 15.5.1 Stars
- 15.5.2 Emerging Leaders
- 15.5.3 Pervasive Players
- 15.5.4 Participants
- 15.5.5 Company Footprint: Key Players, 2025
- 15.5.5.1 Company Footprint
- 15.5.5.2 Region Footprint
- 15.5.5.3 Technology Footprint
- 15.5.5.4 Type Footprint
- 15.5.5.5 Route Of Administration Footprint
- 15.6 Company Evaluation Matrix: Startups/Smes, 2025
- 15.6.1 Progressive Companies
- 15.6.2 Responsive Companies
- 15.6.3 Dynamic Companies
- 15.6.4 Starting Blocks
- 15.6.5 Competitive Benchmarking: Startups/Smes, 2025
- 15.6.5.1 Detailed List Of Key Startups/Smes
- 15.6.5.2 Competitive Benchmarking Of Key Startups/Smes
- 15.7 Company Valuation & Financial Metrics
- 15.7.1 Financial Metrics
- 15.7.2 Company Valuation
- 15.8 Product Comparison
- 15.8.1 Product Comparative Analysis
- 15.9 Competitive Scenario
- 15.9.1 Product Launches & Approvals
- 15.9.2 Deals
- 15.9.3 Expansions
- 16 Company Profiles
- 16.1 Key Players
- 16.1.1 Pfizer Inc.
- 16.1.1.1 Business Overview
- 16.1.1.2 Products Offered
- 16.1.1.3 Recent Developments
- 16.1.1.3.1 Product Approvals
- 16.1.1.4 Mnm View
- 16.1.1.4.1 Key Strengths
- 16.1.1.4.2 Strategic Choices
- 16.1.1.4.3 Weaknesses & Competitive Threats
- 16.1.2 Gsk Plc
- 16.1.2.1 Business Overview
- 16.1.2.2 Products Offered
- 16.1.2.3 Recent Developments
- 16.1.2.3.1 Product Launches & Approvals
- 16.1.2.3.2 Deals
- 16.1.2.3.3 Expansions
- 16.1.2.4 Mnm View
- 16.1.2.4.1 Key Strengths
- 16.1.2.4.2 Strategic Choices
- 16.1.2.4.3 Weaknesses & Competitive Threats
- 16.1.3 Merck & Co., Inc.
- 16.1.3.1 Business Overview
- 16.1.3.2 Products Offered
- 16.1.3.3 Recent Developments
- 16.1.3.3.1 Product Approvals
- 16.1.3.3.2 Expansions
- 16.1.3.4 Mnm View
- 16.1.3.4.1 Key Strengths
- 16.1.3.4.2 Strategic Choices
- 16.1.3.4.3 Weaknesses & Competitive Threats
- 16.1.4 Sanofi
- 16.1.4.1 Business Overview
- 16.1.4.2 Products Offered
- 16.1.4.3 Recent Developments
- 16.1.4.3.1 Product Approvals
- 16.1.4.3.2 Deals
- 16.1.4.3.3 Expansions
- 16.1.4.3.4 Other Developments
- 16.1.4.4 Mnm View
- 16.1.4.4.1 Key Strengths
- 16.1.4.4.2 Strategic Choices
- 16.1.4.4.3 Weaknesses & Competitive Threats
- 16.1.5 Csl
- 16.1.5.1 Business Overview
- 16.1.5.2 Products Offered
- 16.1.5.3 Recent Developments
- 16.1.5.3.1 Product Approvals
- 16.1.5.3.2 Deals
- 16.1.5.3.3 Expansions
- 16.1.6 Emergent
- 16.1.6.1 Business Overview
- 16.1.6.2 Products Offered
- 16.1.6.3 Recent Developments
- 16.1.6.3.1 Product Approvals
- 16.1.6.3.2 Deals
- 16.1.6.3.3 Other Developments
- 16.1.7 Johnson & Johnson Services, Inc.
- 16.1.7.1 Business Overview
- 16.1.7.2 Products Offered
- 16.1.7.3 Recent Developments
- 16.1.7.3.1 Deals
- 16.1.8 Astrazeneca
- 16.1.8.1 Business Overview
- 16.1.8.2 Products Offered
- 16.1.8.3 Recent Developments
- 16.1.8.3.1 Deals
- 16.1.8.3.2 Expansions
- 16.1.9 Serum Institute Of India Pvt. Ltd.
- 16.1.9.1 Business Overview
- 16.1.9.2 Products Offered
- 16.1.9.3 Recent Developments
- 16.1.9.3.1 Product Launches & Approvals
- 16.1.9.3.2 Deals
- 16.1.9.3.3 Expansions
- 16.1.10 Bavarian Nordic
- 16.1.10.1 Business Overview
- 16.1.10.2 Products Offered
- 16.1.10.3 Recent Developments
- 16.1.10.3.1 Product Approvals
- 16.1.10.3.2 Deals
- 16.1.10.3.3 Other Developments
- 16.1.11 Tanabe Pharma Corporation
- 16.1.11.1 Business Overview
- 16.1.11.2 Products Offered
- 16.1.11.3 Recent Developments
- 16.1.11.3.1 Product Launches & Approvals
- 16.1.11.3.2 Deals
- 16.1.12 Daiichi Sankyo Company, Limited
- 16.1.12.1 Business Overview
- 16.1.12.2 Products Offered
- 16.1.12.3 Recent Developments
- 16.1.12.3.1 Deals
- 16.1.13 Panacea Biotec
- 16.1.13.1 Business Overview
- 16.1.13.2 Products Offered
- 16.1.13.3 Recent Developments
- 16.1.13.3.1 Other Developments
- 16.1.14 Biological E. Limited
- 16.1.14.1 Business Overview
- 16.1.14.2 Products Offered
- 16.1.14.3 Recent Developments
- 16.1.14.3.1 Product Approvals
- 16.1.14.3.2 Deals
- 16.1.14.3.3 Other Developments
- 16.1.15 Bharat Biotech
- 16.1.15.1 Business Overview
- 16.1.15.2 Products Offered
- 16.1.15.3 Recent Developments
- 16.1.15.3.1 Product Launches & Approvals
- 16.1.15.3.2 Deals
- 16.1.16 Novavax
- 16.1.16.1 Business Overview
- 16.1.16.2 Products Offered
- 16.1.16.3 Recent Developments
- 16.1.16.3.1 Product Approvals
- 16.1.16.3.2 Deals
- 16.1.17 Inovio Pharmaceuticals
- 16.1.17.1 Business Overview
- 16.1.17.2 Products Offered
- 16.1.17.3 Recent Developments
- 16.1.17.3.1 Other Developments
- 16.2 Other Players
- 16.2.1 Sinovac
- 16.2.2 Incepta Pharmaceuticals Ltd.
- 16.2.3 Valneva Se
- 16.2.4 Eubiologics Co., Ltd.
- 16.2.5 Bio Farma
- 16.2.6 Microgen
- 16.2.7 Chongqing Zhifei Biological Products Co., Ltd.
- 16.2.8 Indian Immunologicals Limited
- 17 Research Methodology
- 17.1 Research Data
- 17.1.1 Secondary Data
- 17.1.1.1 Key Secondary Sources
- 17.1.1.2 Key Data From Secondary Research
- 17.1.2 Primary Data
- 17.1.2.1 Key Primary Participants
- 17.1.2.2 Breakdown Of Primary Interviews
- 17.1.2.3 Key Data From Primary Sources
- 17.2 Market Size Estimation
- 17.2.1 Global Vaccines Market Size Estimation, 2025
- 17.2.1.1 Approach 1: Company Revenue Analysis-based Estimation (Bottom-up Approach)
- 17.2.1.2 Approach 2: Primary Research
- 17.2.1.2.1 Key Industry Insights
- 17.2.1.3 Approach 3: Secondary Analysis
- 17.2.1.4 Approach 4: Bottom-up Approach (Disease Indication-based Analysis)
- 17.2.1.5 Approach 5: Marketsandmarkets Repository Analysis
- 17.2.2 Segmental Market Size Estimation (Top-down Approach), 2025
- 17.3 Market Growth Rate Projections
- 17.4 Data Triangulation
- 17.5 Research Assumptions
- 17.6 Research Limitations & Risk Assessment
- 18 Appendix
- 18.1 Discussion Guide
- 18.2 Knowledgestore: Marketsandmarkets’ Subscription Portal
- 18.3 Customization Options
- 18.4 Related Reports
- 18.5 Author Details
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
